Karyopharm Therapeutics (NASDAQ:KPTI) issued its earnings results on Tuesday. The company reported ($0.71) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.26, Morningstar.com reports. The firm had revenue of $9.49 million during the quarter. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%.
Shares of NASDAQ:KPTI traded up $0.40 during midday trading on Wednesday, hitting $8.70. 1,687,027 shares of the stock were exchanged, compared to its average volume of 1,846,875. The firm has a market cap of $510.01 million, a PE ratio of -2.77 and a beta of 2.40. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19. The business’s 50-day simple moving average is $7.76. Karyopharm Therapeutics has a 12 month low of $3.92 and a 12 month high of $21.71.
Several large investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 12.4% during the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock worth $72,000 after purchasing an additional 1,319 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Karyopharm Therapeutics by 31.3% during the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after purchasing an additional 2,411 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Karyopharm Therapeutics by 20.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock worth $419,000 after purchasing an additional 3,400 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Karyopharm Therapeutics by 8.6% during the second quarter. Wells Fargo & Company MN now owns 60,384 shares of the company’s stock worth $361,000 after purchasing an additional 4,761 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Karyopharm Therapeutics by 6.3% during the second quarter. Swiss National Bank now owns 90,550 shares of the company’s stock worth $542,000 after purchasing an additional 5,400 shares during the last quarter. Institutional investors own 83.86% of the company’s stock.
Several research analysts have commented on the company. JPMorgan Chase & Co. raised Karyopharm Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $8.00 to $16.00 in a research note on Tuesday, July 23rd. Wedbush boosted their target price on Karyopharm Therapeutics from $6.00 to $11.00 in a research note on Monday, July 8th. ValuEngine raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 13th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 target price (up previously from $29.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $18.53.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.